IMPELLO BIOSCIENCES, INC. – Trademark Portfolio
Entity Type: 03
IMPELLO BIOSCIENCES, INC. holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 6 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 4 trademarks are registered and 2 are pending. Notable registered marks include TRIBUS, BIOFUEL, IMPELLO, and MICRO ORGANISMS FOR MACRO YIELDS. The owner is based in Loveland, CO.
900 Josephine Court, Unit 2
Loveland, CO 80537
Showing of trademarks Trademarks
Trademark Classifications
IMPELLO BIOSCIENCES, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does IMPELLO BIOSCIENCES, INC. have?
IMPELLO BIOSCIENCES, INC. has 8 U.S. trademarks filed with the USPTO. Of these, 4 registered, 2 pending, 2 abandoned.
What trademark classes does IMPELLO BIOSCIENCES, INC. file in?
IMPELLO BIOSCIENCES, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are IMPELLO BIOSCIENCES, INC.'s most well-known trademarks?
IMPELLO BIOSCIENCES, INC.'s registered trademark portfolio includes well-known marks such as TRIBUS, BIOFUEL, IMPELLO, and MICRO ORGANISMS FOR MACRO YIELDS. These are among 4 currently registered trademarks in the portfolio.
What is IMPELLO BIOSCIENCES, INC.'s trademark registration success rate?
IMPELLO BIOSCIENCES, INC. has a 67% trademark registration rate, with 4 out of 6 resolved applications resulting in successful registration. Currently, 2 applications are pending review.